within Pharmacolibrary.Drugs.C_CardiovascularSystem.C09D_AngiotensinIiReceptorBlockersArbsCombinations.C09DB01_ValsartanAndAmlodipine;
model ValsartanAndAmlodipine 
   extends Pharmacolibrary.Drugs.ATC.C.C09DB01;

  annotation(Documentation(
    info ="<html><body><p>Valsartan and amlodipine is a fixed-dose combination of two antihypertensive agents: valsartan, an angiotensin II receptor blocker (ARB), and amlodipine, a calcium channel blocker. The combination is widely approved and used for the treatment of hypertension to lower blood pressure and reduce the risk of cardiovascular events.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult subjects after oral administration of fixed-dose combination tablets. No direct publication was found reporting population PK models for the combination tablet, so estimates are from separate published PK data of valsartan and amlodipine monotherapies.</p><h4>References</h4><ol><li><p>Duan, J, et al., &amp; Sunkara, G (2012). Pharmacokinetics of single and multiple oral doses of valsartan/amlodipine (80/5 mg) in healthy Chinese subjects. <i>International journal of clinical pharmacology and therapeutics</i> 50(1) 33–43. DOI:<a href=&quot;https://doi.org/10.5414/cp201601&quot;>10.5414/cp201601</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22192643/&quot;>https://pubmed.ncbi.nlm.nih.gov/22192643</a></p></li><li><p>Ngo, L, et al., &amp; Lee, YB (2018). Effects of hydrochlorothiazide and amlodipine on single oral dose pharmacokinetics of valsartan in healthy Korean subjects: Population model-based approach. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 118 154–164. DOI:<a href=&quot;https://doi.org/10.1016/j.ejps.2018.03.031&quot;>10.1016/j.ejps.2018.03.031</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29604332/&quot;>https://pubmed.ncbi.nlm.nih.gov/29604332</a></p></li><li><p>Tian, M, et al., &amp; Yang, S (2025). Pharmacokinetics and Bioequivalence of Two Fixed-Dose Combination Tablets of Valsartan/Amlodipine (80/5 Mg) in Healthy Chinese Subjects. <i>Drug design, development and therapy</i> 19 11–22. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S485851&quot;>10.2147/DDDT.S485851</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39781445/&quot;>https://pubmed.ncbi.nlm.nih.gov/39781445</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end ValsartanAndAmlodipine;
